ClinicalTrials.Veeva

Menu

Bifeprunox in the Treatment of Schizophrenia

S

Solvay

Status and phase

Completed
Phase 3

Conditions

Schizophrenia

Treatments

Drug: bifeprunox

Study type

Interventional

Funder types

Industry

Identifiers

NCT00193713
S154.3.004

Details and patient eligibility

About

Study of the long-term efficacy and safety of bifeprunox in the treatment of schizophrenia.

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • diagnosis of schizophrenia
  • understand nature of study
  • able to be managed in out-patient setting for long-term bifeprunox treatment

Exclusion criteria

  • current primary diagnosis other than schizophrenia
  • suicide risk
  • diagnosis or history of substance abuse
  • uncontrolled hypertension

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems